The chains announced the data breach Friday morning. The massive hack impacts their umbrella of stores, as well.
That includes Albertson's Acme, Jewel-Osco, Shaw's and Star Market supermarkets, as well as SuperValu's Cub Foods, Hornbacher's, Farm Fresh, Shop 'N Save and Shoppers Food & Pharmacy.
The extent of the damage isn't yet clear, and the grocery chains haven't yet said how many customers might be affected. SuperValu said it knows hackers broke into the computer network that processes card payments, but it's unsure whether they managed to take the data.
Top 5 Construction Companies To Buy Right Now: Washington Banking Company(WBCO)
Washington Banking Company operates as the bank holding company for Whidbey Island Bank that provides community commercial banking services in northwestern Washington. Its deposit products include interest-bearing demand and money market accounts, saving deposits, time deposits, NOW accounts, and noninterest-bearing demand deposits. The company?s portfolio of loans comprises secured and unsecured commercial loans for working capital and expansion; real estate mortgage loans, including one-to-four family residential and commercial real estate loans; and real estate construction loans, such as commercial real estate, one-to-four family residential construction, and speculative construction loans. Its consumer loan portfolio include automobile loans, boat and recreational vehicle financing, home equity and home improvement loans, and other secured and unsecured personal loans, as well as SBA guaranteed loans for small and medium sized businesses. In addition, the company pro vides non-deposit managed investment products and services, and sweep investment options. As of December 31, 2010, it operated 30 branches in 6 counties located in northwestern Washington. The company was founded in 1996 and is based in Oak Harbor, Washington.
Advisors' Opinion:- [By Eric Volkman]
Washington Banking (NASDAQ: WBCO ) is diverting some of its capital to repurchase its own stock. The company announced that its board has authorized a buyback program for up to 775,000 shares. The program is expected to continue through the end of 2014, although the firm stressed that it "is under no obligation to repurchase a specific number or dollar amount of shares and the repurchase program may be discontinued at any time."
5 Best Supermarket Stocks For 2014: Endocyte Inc.(ECYT)
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. The company?s principal SMDC product candidate, EC145, has been evaluated in a randomized Phase II clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a Phase II single-arm clinical trial for pre-treated non-small cell lung cancer. Its preclinical development products include EC0489 and EC0225, which are in Phase I clinical trial for the treatment of solid cancer tumors; EC17 that has completed Phase I clinical trial for the treatment of solid cancer tumors; EC0531, a tubulysin conjugate to treat solid tumors; and EC0746 and EC0565 foliate receptors for the reduction o f inflammation. The company?s products under development also comprise EC20, a proprietary companion imaging diagnostic product for the identification of folate receptor in cancer patients; EC1069 for prostate cancer therapy; and EC0652 that is in early clinical trials for use as a companion imaging diagnostic for SMDCs. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.
Advisors' Opinion:- [By Roberto Pedone]
��
An under-$10 biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Endocyte (ECYT), which develops targeted therapies for the treatment of cancer and inflammatory diseases in the U.S. This stock is off to a nasty start in 2014, with shares down sharply by 35%.
If you take a look at the chart for Endocyte, you'll see that this stock has been trending sideways and consolidating for the last month and change, with shares moving between $6.01 on the downside and right around $7.30 on the upside. This consolidation pattern is coming after shares of ECYT gapped down sharply in May from over $17.50 to $6.50 a share with heavy downside volume. Shares of ECYT are now starting to trend higher off its recent low of $6.05 and it's quickly moving within range of triggering a major breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in ECYT if it manages to break out above some near-term overhead resistance at $7.30 a share with high volume. Look for a sustained move or close above that level with volume that registers near or above its three-month average action of 1.90 million shares. If that breakout materializes soon, then ECYT will set up to re-fill some of its previous gap-down-day zone from early May that started at just above $17.50 a share. Some possible upside targets if ECYT gets into that gap with volume are $9 to $10 a share, or even its 50-day moving average of $12.10 a share.
Traders can look to buy ECYT off weakness to anticipate that breakout and simply use a stop that sits right below its recent 52-week low of $6.01 a share. One can also buy ECYT off strength once it starts to take out $7.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Endocyte (NASDAQ: ECYT ) has received a distressing two-star ranking.
- [By Jon C. Ogg]
Endocyte Inc. (NASDAQ: ECYT) is trading like the company is being acquired. This is proof that any biotech with great cancer drug news can run, regardless of market conditions. It and Merck & Co. (NYSE: MRK) have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for conditional marketing approval of Vynfinit (or vintafolide) and companion imaging components, imaging agent Folcepri (or etarfolatide), and Neocepri (intravenous folic acid), for the treatment of adult patients with ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).
5 Best Supermarket Stocks For 2014: Salix Pharmaceuticals Ltd (SLXP)
Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Xifaxan (rifaximin) tablets
Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.
It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.
In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.
MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution
MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.
Apriso (mesalamine) extended-release capsules 0.375 gram
Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.
Relistor (methylnaltrexone bromide)
Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.
OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets
Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.
Solesta
Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.
Deflux
Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.
Fulyzaq (crofelemer) delayed-release tablets
On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.
Giazo (balsalazide disodium) tablets
February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.
Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets
METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.
Azasan (azathioprine) tablets
Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.
Anusol-HC and Proctocort (hydrocortisone) creams and suppositories
The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.
Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)
Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.
Colazal (balsalazide disodium) capsules
The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.
The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.
Advisors' Opinion:- [By David Williamson]
In this segment, health-care analyst David Williamson takes a look at the upcoming acquisition by Salix Pharmaceuticals (NASDAQ: SLXP ) of Santarus (NASDAQ: SNTS ) for about $2.6 billion. Salix is currently a maker of drugs for gastrointestinal diseases, and the immediately accretive deal will give Salix access to treatments for both diabetes and heartburn. Shares of both companies were up significantly on the news. David tells investors why shareholders should be pleased with this deal on both ends and what he thinks of the stock going forward.
- [By Jake L'Ecuyer]
Equities Trading UP
Santarus (NASDAQ: SNTS) shot up 37.95 percent to $32.03 after Salix Pharmaceuticals (NASDAQ: SLXP) announced its plans to buy Santarus for around $2.12 billion. Santarus and Pharming also announced new data from open-label repeat treatment study with RUCONEST. - [By Paul Ausick]
Stocks on the Move: Twitter Inc. (NYSE: TWTR) is down 7.3% at $41.64 on its second day of trading and word is that some hedge funds and traders are looking to borrow shares. Santarus Inc. (NASDAQ: SNTS) is up 37.6% at $31.95 after agreeing late Thursday night to an acquisition by Salix Pharmaceuticals Inc. (NASDAQ: SLXP) for $2.6 billion in cash.
- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares shot up 5.52 percent to $168.66 on report of takeover talks with Allergan. Allergan (NYSE: AGN) is set to acquire Salix Pharmaceuticals in a deal probably worth more than $10 billion, according to Dow Jones Newswires.
5 Best Supermarket Stocks For 2014: IDGlobal Corp (IDGC)
ID Global Corporation (IDGC), incorporated on March 1, 2006, is a diversified holdings company with a focus on emerging and middle market investment opportunities in North America. The Company seeks to invest in emerging and private companies. The Company acts as a catalyst between the companies to raise and infuse capital when required.
The Company offers finance, social media and eco friendly products so that companies can independently manage and operate their business. IDGC through its debt and equity investments, controls interests in private companies, as well as special situation start-ups.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks IDGlobal Corp (OTCMKTS: IDGC), Embarr Downs Inc (OTCMKTS: EMBR) and SourcingLink.net, Inc (OTCMKTS: SNET) have been getting some extra attention in various investment newsletters or investor alerts lately as at least two of these stocks have been the subject of paid promotions or other types of investor relations activities. Of course, there is nothing wrong with properly disclosed promotions or investor relations activities. But just how hot are these two small cap stocks? Here is a closer look and a quick reality check:
No comments:
Post a Comment